Research News

Latest Advances in Lung Cancer Research

Explore our curated selection of the latest breakthroughs in lung cancer research.

Clear Filter
  • February 10, 2021

    Exploring Saliva in Early Lung Cancer Detection

    Exploring saliva in early lung cancer detection: UCLA School of Dentistry researchers are looking at saliva for its diagnostic possibilities.

    Medical Device and Diagnostic Industry

  • February 2, 2021

    Racial Disparities in Lung Cancer

    A sizable body of research has long shown racial disparities in treatment and survival between Black and White patients with lung cancer.

    Pulmonology Advisor

  • January 26, 2021

    Lung Cancer Stigma: 10 Year Study

    Lung cancer stigma negatively impacts the clinical care and outcomes of those diagnosed, resulting in enduring disparities.

    The Journal of Thoracic Oncology

    Advocacy Diagnosis Disparities
  • January 26, 2021

    ‘But I never smoked’: Never smokers and lung cancer

    Lung cancer in never smokers is becoming more prominent – especially in women. 12% of U.S. lung cancer patients are never-smokers and it is increasing.


    Detection Lung Cancer Info Prognosis Risks
  • January 12, 2021

    Lung Cancer Screenings Are Down

    Lung cancer screenings down due to COVID. Drop in lung cancer screenings due to canceled or postponed services has led to worse patient outcomes.

    Diagnostic Imaging

  • January 8, 2021

    Trailblazer KRAS treatment filed with FDA

    Amgen has filed its trailblazer KRAS inhibiting drug treatment with the FDA for a group of lung cancer patients with an aggressive form of the disease.


    Targeted Therapy Treatment

Get the latest lung cancer research news directly in your inbox.

Learn more about:

  • the latest science in lung cancer
  • stories about living with lung cancer
  • how LCFA is working to fund more lung cancer research grants

LCFA prioritizes providing reliable information about new diagnostics, treatments, and prevention strategies, including exciting FDA-approved personalized therapies based on individual tumor biomarkers.